Lei Hong

Dr. Lei Hong


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Frontiers in Microbiology
Verified
Journal Article
Open access
JMJiawei Ma
Jiawei Ma
ZZZigang Zhu
Zigang Zhu
YYYisikandeer Yishajiang
Yisikandeer Yishajiang
KAKhaloud Mohammed Alarjani
Khaloud Mohammed Alarjani
LHLei Hong
Lei Hong
LLLiang Luo
Liang Luo
Background: Acute respiratory distress syndrome (ARDS) is a serious lung ailment marked by significant inflammation and damage in the alveoli and capillaries of the lungs. Recent research suggests a strong correlation between the onset and advancement of ARDS and an imbalance in the gut microbiota (GM).Methods: In this investigation, Mendelian randomization (MR) analysis was utilized, drawing on data from publicly accessible genome-wide association studies. The primary focus was on examining the interplay between GM, inflammatory factors (IFs) and ARDS. Instrumental variables were established through genetic modifications of GM and IFs. Various statistical analysis methods including the inverse-variance weighted model, MR-Egger method and Wald ratio test were applied for comprehensive data analysis.Results: Eight bacterial taxa within the GM demonstrated a potential causal link with development of ARDS. Notably, the phylum Actinobacteria and the genus Intestinibacter exhibited a negative association with the risk of ARDS. However, Erysipelotrichales (id. 2,148), Victivallis (id. 2,256), Ruminococcaceae UCG014 (id. 11,371), Eubacterium ruminantium group (id. 11,340), Erysipelotrichaceae (id. 2,149) and Erysipelotrichia (id. 2,147) demonstrated a positive association with ARDS risk. Additionally, the study identified a potential causal relationship between the inflammatory factors interleukin-16 and C-C motif chemokine 3 with the occurrence of ARDS.Conclusion: This study strongly suggests that the interaction between gut microbiota (GM) and inflammatory factors (IFs) significantly contributes to the pathogenesis of acute respiratory distress syndrome (ARDS). This underscores their crucial involvement in both the initiation and advancement of this severe lung disorder.

1 January 2021 in Bioengineered
Verified
Journal Article
Open access
JMJiawei Ma
Jiawei Ma
QLQianqian Li
Qianqian Li
DJDandan Ji
Dandan Ji
LLLiang Luo
Liang Luo
LHLei Hong
Lei Hong
Sepsis-induced acute respiratory distress syndrome (ARDS) remains a major threat to human health without effective therapeutic drugs. Previous studies demonstrated the power of gene expression profiling to reveal pathological changes associated with sepsis-induced ARDS. However, there is still a lack of systematic data mining framework for identifying potential targets for treatment. In this study, we demonstrated the feasibility of druggable targets prediction based on gene expression data. Through the functional enrichment analysis of microarray-based expression profiles between sepsis-induced ARDS and non-sepsis ARDS samples, we revealed genes involved in anti-microbial infection immunity were significantly altered in sepsis-induced ARDS. Protein–protein interaction (PPI) network analysis highlighted TOP2A gene as the key regulator in the dysregulated gene network of sepsis-induced ARDS. We were also able to predict several therapeutic drug candidates for sepsis-induced ARDS using Connectivity Map (Cmap) database, among which doxorubicin was identified to interact with TOP2A with a high affinity similar to its endogenous ligand. Overall, our findings suggest that doxorubicin could be a potential therapeutic for sepsis-induced ARDS by targeting TOP2A, which requires further investigation and validation. The whole study relies on publicly available dataset and publicly accessible database or bioinformatic tools for data mining. Therefore, our study benchmarks a workflow for druggable target prediction which can be widely applicable in the search of targets in other pathological conditions. Graphical Abstract

10 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MGMing-Cheng Guan
Ming-Cheng Guan
NLNa Li
Na Li
QDQian Ding
Qian Ding
DSDi Sun
Di Sun
HLHao Li
Hao Li
HZHong Zhu
Hong Zhu
Background: The heterogeneous efficacy of immunotherapy in hepatocellular carcinoma (HCC) remains unclear. We evaluated efficacy and safety of various immunotherapeutic regimens—including immune checkpoint inhibitor (ICI) monotherapy, dual ICIs, and ICI plus targeted therapy—for unresectable HCC, to identify patient subgroups that benefit most. Methods: Randomized clinical trial evaluating immunotherapy as first-line treatment for unresectable HCC versus tyrosine kinase inhibitors (TKIs) were systematically searched. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) were calculated. Results: Twelve trials were included. Immunotherapy significantly improved OS (HR = 0.77 [0.71-0.83]) and PFS (HR = 0.73 [0.63-0.84]) versus TKIs. ICI plus targeted therapy showed the greatest benefit, reducing mortality by 27% and progression risk by 37%. Subgroup analyses revealed patients aged ≥65 years and male patients derived substantial OS and PFS benefits, particularly from ICI plus targeted therapy, whereas younger patients (<65 years) benefited more from dual ICIs. Additional favorable subgroups included Asian patients, HBV-positive patients, those with poor performance status, macrovascular invasion and/or extrahepatic spread, and Barcelona Clinic Liver Cancer stage C. Notably, female patients showed no significant OS improvement across any regimen. Moreover, non-Asian patients, those with hepatitis C, BCLC stage B, or AFP <400 ng/mL derived limited immunotherapy benefit across regimens. Conclusions: Immunotherapy improves survival in unresectable HCC, with differential subgroup benefits highlighting the necessity for personalized strategies. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD42025635108.

30 December 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYu Zhao
Yu Zhao
XZXinying Zhou
Xinying Zhou
LHLei Hong
Lei Hong
JYJinyu Yao
Jinyu Yao
JPJinlin Pan
Jinlin Pan
MSminxuan sun
minxuan sun